Evidence map›Paper›PMID 42707675›Full record

ArticleFrontiers in cardiovascular medicine2026

Metabolism of 2-oxo-clopidogrel to the clopidogrel active H4 metabolite using human liver microsomes and its inhibitory effect on ADP-induced human platelet aggregation

Christian Schulz, Steffen Braune, Christof Mrowietz, Jan-Heiner Küpper, Friedrich Jung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christian Schulz *Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Site Lausitz (IZI-BB-L), Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e. V., Senftenberg, Germany.
Steffen Braune *Institute of Biotechnology, Department of Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Christof MrowietzInstitute of Biotechnology, Department of Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Jan-Heiner KüpperInstitute of Biotechnology, Department of Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Friedrich JungInstitute of Biotechnology, Department of Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clopidogrel is a drug that is commonly used to prevent occlusive events after coronary artery interventions. However, the efficacy of clopidogrel varies depending on the CYP2C19 polymorphism, as it is not clopidogrel itself but the H4 metabolite that is responsible for the pharmacological effect. Carriers of the CYP2C19 loss-of-function allele genotype - which can affect up to 50% of patients - exhibited a higher likelihood of experiencing cardiovascular events. Administering the H4 metabolite directly avoids this problem. In the first step, the H4 metabolite was successfully produced

Indexed as

2-oxo-clopidogrelADP-induced platelet aggregationclopidogrelH4 metabolitehuman liver microsomes

Identifiers

PMID42707675
PMCPMC13547928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.